Related Experiment Video

Updated: Jun 23, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

HER-2 signaling and inhibition in breast cancer

B C Browne1, N O'Brien, M J Duffy

  • 1National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

Current Cancer Drug Targets
|May 16, 2009
PubMed

Insights

HER-2 gene amplification drives aggressive breast cancer. While therapies like trastuzumab target HER-2, resistance limits effectiveness, necessitating new therapeutic strategies for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER-2 gene amplification in 25% of breast cancers drives aggressive disease and poor prognosis.
  • HER-2 overexpression necessitates targeted therapeutic approaches.
  • Trastuzumab, an FDA-approved HER-2 antibody, shows limited efficacy due to resistance.

Purpose of the Study:

  • To review current understanding of HER-2 signaling in breast cancer.
  • To explore mechanisms of resistance to HER-2 targeted therapies.
  • To discuss novel therapeutic strategies for overcoming resistance.

Main Methods:

  • Review of preclinical and clinical studies on HER-2 targeted therapies.
  • Analysis of resistance mechanisms in cell line models.
  • Evaluation of emerging HER-2 antagonists.

Main Results:

  • HER-2 overexpression correlates with aggressive breast cancer phenotypes.
  • Trastuzumab resistance develops within a year for most patients.
  • Novel HER-2 antagonists, including small molecules and antibodies, are in development.

Conclusions:

  • Understanding HER-2 signaling and resistance is crucial for developing effective breast cancer treatments.
  • Targeting HER-2 remains a key strategy, with ongoing research into overcoming resistance.
  • New therapeutic agents targeting HER-2 are essential for improving patient survival and treatment efficacy.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...